Volume 4, Number 1 January 1991

JTSTEB 4(1) 1–162 (1991)
ISSN 0894-9867

Journal of Traumatic Stress

PLENUM PRESS • NEW YORK–LONDON

Journal of Traumatic Stress, Vol. 4, No. 1, 1991

Biological Approaches to the Diagnosis and Treatment of Post-Traumatic Stress Disorder

Matthew J. Friedman[1]

[Accepted June 14, 1989]

Post-Traumatic Stress Disorder appears to be associated with biological alterations in central noradrenergic activity, the hypothalamic-pituitary-adrenocortical axis, the endogenous opioid system, and the sleep cycle. This pattern of biologic abnormalities, which appears unique to PTSD, has practical implications for diagnosis and treatment. A biological approach may complement psychological diagnostic techniques. With regard to treatment, almost every type of psychotropic agent has reported efficacy in PTSD. However, very few double-blind therapeutic trials have been published. Successful pharmacotherapy appears to alleviate DSM-III-R intrusive recollections and hyperarousal but not avoidant symptoms. Current information suggests that drug treatment alone can rarely alleviate the suffering in PTSD. Medication appears to be most useful as an adjunct to psychotherapy. Finally, the neurobiological alterations associated with PTSD may make affected individuals more susceptible to alcohol, opiates, and other illicit drug use. This also has important implications for treatment.

KEY WORDS: PTSD; diagnostic tests; pharmacotherapy; noradrenergic system; endogenous opioid system; hypothalamic-pituitary-adrenocortical system; sleep cycle; alcohol and chemical abuse/dependency.

INTRODUCTION

Biological approaches to the diagnosis and treatment of PTSD are receiving increasing attention from scientists and clinicians. Research findings appear

[1]Executive Director, National Center for PTSD, Veterans Administration Hospital, White River Junction, Vermont 05001; and Professor of Psychiatry and Pharmacology, Dartmouth Medical School, Hanover, New Hampshire 03756.

0894-9867/91/0100-0067$06.50/0

to suggest that patients with PTSD display marked abnormalities in sympathetic nervous system arousal, in hypothalamic-pituitary-adrenocortical function, in the endogenous opioid system, and in the physiology of sleep and dreaming. Such results enable us to expand our theoretical understanding of PTSD from a purely psychological context to a bio-psycho-social model in which many different factors contribute to the pathology of PTSD.

In this article I will review current advances in biological research on PTSD. I will demonstrate how a biological perspective may complement psychological diagnostic techniques to achieve greater precision in identifying PTSD. This is especially pertinent in distinguishing PTSD from either major depressive disorder (MDD) or panic disorder (PD) since PTSD exhibits many of the same symptoms as each of these other psychiatric illnesses.

I will also review current knowledge on pharmacotherapy of PTSD in the context of our present understanding of the unique pathophysiology of this disorder. Neurobiological models also suggest why patients with PTSD may be particularly susceptible to alcohol and other chemical abuse/dependency. Such theoretical considerations will be reviewed in the context of treatment implications of patients with the dual diagnosis of PTSD and chemical abuse/dependency.

HISTORICAL PERSPECTIVE

Abraham Kardiner's research on World War I veterans during the 1940's has proved to be highly influential in stimulating modern biological approaches to PTSD (Kardiner, 1941; Kardiner and Spiegel, 1947). Theorizing from the psychological perspective of stress and adaptation, Kardiner stated that (what is now called) PTSD was a "physioneurosis" in which the patient's adaptive capacity was "smashed." He believed that PTSD was both a psychological and a physiological disorder with its own unique pathophysiology. To underscore this biological orientation Kardiner labeled the dissociative episodes now called flashbacks as an "epileptic symptom complex" implying that they were caused by some disorder of brain function.

A few years later Cohen *et al.* investigated neurocirculatory asthenia (NCA) on a clinical population consisting mostly of combat veterans (Cohen *et al.*, 1948; Cohen and White, 1950). Placing their work in a historical context of physiological and medical research on combat survivors dating back to the Civil War (Beard, 1869; DaCosta, 1871; Hartshorne, 1864; Lewis, 1917; Wood, 1941), they recognized that NCA had previously had many other names including soldier's heart, anxiety neurosis, nervous exhaustion, DaCosta's Syndrome, irritable heart, and effort syndrome. Cohen and asso-

ciates elegantly showed that combat veterans with NCA had many abnormalities that could be readily detected when they were asked to perform muscular work on a treadmill. Patients with NCA (a) could not work as long as controls, (b) had a metabolic defect evidenced by less efficient oxygen consumption and higher blood lactate concentration, (c) had reduced pulmonary ventilatory efficiency, (d) had excessively high pulse rates during work, and (e) showed abnormal reactivity to painful stimuli.

Since most of their subjects were World War II veterans, Cohen and associates speculated about the possible impact of military experience on their experimental observations. They noted that many of their subjects had been in good health before the onset of NCA. They also noted that the vast majority of their subjects "blamed the army for their difficulties" and that "a high percentage of patients . . . reported a harrowing experience in combat" (Cohen *et al.*, 1948, p. 278). Other subjects suggested that family violence, death, and illness preceded the onset of NCA. Cohen *et al.* never went beyond such preliminary observations to explore the possibility that exposure to trauma was the common denominator for many of their subjects. They were apparently unaware of Kardiner's work on the impact of combat trauma and concluded that the cause of NCA was "unknown."

These important early investigations by Cohen *et al.* have recently been rediscovered by researchers studying the pathophysiology of panic disorder. Perhaps Cohen *et al.'s*, assertion that NCA had no known etiology accounts for the fact that their work is seen as a pioneering effort in the field of panic disorder rather than PTSD. However, recent findings with PTSD patients by biologically oriented investigators suggest that the work of Cohen *et al.* is also relevant to PTSD. With regard to cardiovascular function, Israeli combat veterans with PTSD exhibit low effort tolerance and decreased cardiac reserve in comparison with controls (Shalev *et al.*, 1990). Burn patients with PTSD have significantly lower pain thresholds than burn patients without PTSD (Perry *et al.*, 1987). Reports of a possible link between chronic pain and PTSD (Benedikt and Kolb, 1986; Rapaport, 1987) are also consistent with these observations of hyperalgesia among PTSD patients. Finally reports of higher rates of somatic complaints among Israeli combat veterans with PTSD (Solomon and Mikulincer, 1987) update similar observations by Cohen *et al.* (1948) among World War II veterans with NCA.

These clinical observations indicate how exposure to trauma may alter the body's normal physiology and health. At face value, such findings suggest that the port of entry into our health care system for some PTSD patients may be via cardiac, pain, or other medical clinics. At another level, of course, such findings suggest that PTSD is associated with a number of biological alterations that may be expressed somatically as well as psychiatrically.

Table I. Biological Alterations Associated with PTSD

1. Sympathetic nervous system hyperarousal
   a. Elevated baseline sympathetic physiological indices.
   b. Sympathetic psychophysiological response upon exposure to traumagenic stimuli.
   c. Elevated urinary catecholamine levels.
   d. Reduced platelet MAO activity.
   e. Down-regulation of adrenergic receptors.
2. Hypofunction of hypothalamic-pituitary-adrenocortical axis
   a. Decreased urinary cortisol levels.
   b. HPA suppression following dexamethasone.
   c. Unique elevation of urinary catecholamine/cortisol ratio.
3. Abnormalities of the endogenous spioid system
   a. Stress induced analgesia by traumagenic stimuli.
   b. General lowering of the pain threshold at rest.
4. Sleep abnormalities
   a. Initiating and maintaining sleep:
      increased sleep latency, decreased total sleep time,
      decreased sleep efficiency, increased number of awakenings, increased body movements.
   b. Sleep architecture: changes are controversial.
   c. Traumatic nightmares are unique.

BIOLOGICAL ALTERATIONS ASSOCIATED WITH PTSD

Sympathetic Nervous System

Dysregulation of the sympathetic nervous system has been demonstrated by monitoring the psychophysiological response of combat veterans upon exposure to traumagenic stimuli, by measuring urinary catecholamine levels, and by determination of peripheral alpha 2 and beta-adrenergic receptor binding in patients with PTSD (Table I).

A thorough discussion of this research is beyond the scope of this article and the reader is referred to Kolb's (1987) elegant recent review for more information. Briefly, uncontrolled findings on combat veterans with PTSD include increased muscle tension (Gillespie, 1942) and increased heart rate, respiration rate and EEG alpha rhythm (Dobbs and Wilson, 1961). A major methodological breakthrough occurred when Blanchard *et al.* (1982) recognized that the hallmark of PTSD is a conditioned emotional response to meaningful stimuli that trigger thoughts, memories and feelings uniquely associated to the trauma itself. They have shown that at baseline, Vietnam combat veterans with PTSD exhibit higher heart rate, systolic blood pressure, and forehead EMG than controls. More importantly, PTSD patients exhibit dramatic physiological arousal after exposure to an audiotape of combat sounds played at gradually increasing volume levels. The heart rate, systolic blood pressure, and EMG responses of

PTSD patients were so much greater than controls that blind raters correctly classified them 95.5% of the time. Similar results have been obtained in other laboratories (Brende, 1982; Malloy *et al.*, 1983). Psychophysiological arousal in Vietnam combat veterans with PTSD has also been elicited by other traumagenic stimuli (Pitman *et al.*, 1987, 1988).

One would predict that sympathetic psychophysiological hyper-reactivity would be associated with elevated catecholamine levels. Indeed elevated urinary norepinephrine (Kosten *et al.*, 1987; Mason *et al.*, 1985) and epinephrine levels (Kosten and Krystal, 1988; Kosten *et al.*, 1988) have been found in Vietnam combat veterans with PTSD. Kosten *et al.* (1987) reported that 24-hr urinary norepinephrine and epinephrine levels in PTSD patients were significantly higher than those of normals and of patients with panic disorder, major depressive disorder, undifferentiated schizophrenia, paranoid schizophrenia, and manic-type bipolar disorders. Mason and associates (1985) had previously reported that PTSD patients have a higher urinary norepinephrine/cortisol ratio. This ratio results both from elevated urinary norepinephrine levels and from the reduced urinary cortisol levels that are uniquely found in PTSD patients (Mason *et al.*, 1986—see below).

Whereas elevated catecholamine levels may be biochemical markers for the sympathetic dysregulation association with PTSD, they may also reflect another abnormality, reduced monoamine oxidase activity (MAO) in combat veterans with PTSD. Since MAO is a major degradative enzyme in catecholamine metabolism, reduced MAO could lead to higher systemic norepinephrine and epinephrine levels. In this regard, Davidson and associates (1985) reported a significant reduction in platelet MAO activity among combat veterans with PTSD. As discussed by Kosten and Krystal (1988) interpretations of these findings must be cautious because of the simultaneous occurrence of depression and/or alcoholism in many of these patients.

Finally, three studies on adrenergic receptor binding are consistent with all of the above results suggesting that PTSD is associated with higher sympathetic nervous function. One would predict that increased adrenergic synaptic activity should desensitize or down-regulate adrenergic receptors. Consistent with this prediction, Perry *et al.* (1987) observed fewer total platelet alpha 2 receptor binding sites in 12 Vietnam veterans with PTSD as compared with 13 age-matched controls. In addition to down regulation, Perry *et al.* (1988) showed in a more recent report that the alpha 2 receptor complex is uncoupled and therefore functions less efficiently in the platelets of patients with PTSD. Similarly, Lerer and associates (1987) studied beta-adrenergic receptor binding in both intact lymphocytes and platelet membrane preparations. They found that PTSD patients exhibited abnormally low beta-adrenergic receptor mediated cAMP signal transduction.

Hypothalamic-Pituitary-Adrenocortical (HPA) Axis

Turning from the sympathetic nervous system to the hypothalamic-pituitary-adrenocortical (HPA) axis, data on urinary cortisol levels and the dexamethasone suppression test (DST) suggest that hypofunction of the HPA axis is associated with PTSD. Mason and associates (1986) have shown that 24-hr urinary free-cortisol levels are significantly lower among PTSD patients than in most other psychiatric disorders. Furthermore normal suppression of the HPA axis by dexamethasone has been shown in PTSD patients (Kudler *et al.*, 1987). Two theoretical explanations have been proposed to explain HPA axis hypofunction in PTSD. Mason *et al.* (1986) have cited older psychosomatic research suggesting that denial and psychological defenses can exert a strong suppressive effect upon urinary corticosteroid levels. A more parsimonious hypothesis postulates that biological rather than psychological mechanisms may account for HPA axis hypofunction. This argument is based on the previously discussed possibility that PTSD is associated with increased central noradrenergic activity. Since norepinephrine inhibits the release of corticotropin-releasing hormone, CRH (Price *et al.*, 1986), the postulated increased central sympathetic activity of PTSD would be expected to inhibit the entire HPA system.

Endogenous Opioid System

Kosten and Krystal (1988) have suggested that adrenergic inhibition of CRH may also account for a disturbance in the endogenous opioid system associated with PTSD. CRH promotes release of ACTH from the pituitary; ACTH is coreleased with betaendorphin which influences the activity level of the endogenous opioid system. Therefore, Kosten and Krystal postulate that inhibition of CRH by excessive sympathetic arousal will also produce an endogenous opioid deficiency in patients with PTSD. This prediction is consistent with previously mentioned clinical reports of lowered pain thresholds in PTSD patients (Perry et al., 1987) and of a possible link between chronic pain and PTSD (Benedikt and Kolb, 1986; Rapaport, 1987). Finally, Pitman and associates (1990) have recently shown that exposing Vietnam veterans with PTSD to combat scenes from the movie *Platoon* produces a naloxone-reversible 30% decrease in pain responses. This important finding of stress-induced analgesia suggests not only that PTSD is associated with dysregulation of the endogenous opioid system but also that a possible baseline opioid deficiency might be dramatically reversed when PTSD patients are exposed to traumagenic stimuli.

Sleep and Dreaming

Abnormalities in sleep and dreaming also appear to be associated with PTSD. Patients often have difficulty initiating and maintaining sleep (Table I). In addition, several studies show marked disruption of sleep architecture in PTSD exemplified by increased Stage 1, increased Stage 2, decreased Delta sleep, decreased REM latency, and increased total REM percent (Lavie *et al.*, 1979; Kramer *et al.*, 1982; Kramer and Kinney, 1985, 1988; Schlossberg and Benjamin, 1978). These results are controversial, however, especially with regard to REM latency and total REM percent (Greenberg *et al.*, 1972; Van Kammen *et al.*, 1987). An excellent review by Ross *et al.* (1989) clarifies methodological problems and substantive contradictions on the emerging literature on sleep in PTSD.

In addition to alterations in physiological sleep, disturbed dreaming is a prominent abnormality in chronic PTSD (Kramer, 1979; van der Kolk *et al.*, 1984). Traumatic nightmares may arise out of REM or non-REM (NREM) sleep (van der Kolk *et al.*, 1984). As noted earlier (Friedman, 1981) these nightmares appear to be unique to PTSD since they are neither REM dream anxiety attacks nor NREM night terror/nightmares (Kramer, 1979). On the other hand, Ross *et al.* (1989) suggest that PTSD nightmares may actually be a newly identified phenomenon called REM sleep without atonia. The signifying characteristic of the PTSD nightmare is an "instant-replay" of the traumatic event often accompanied by nocturnal muscle movements that are consonant with the events of the nightmare.

Neurobiological Models of PTSD

A number of models have been proposed to integrate the biological abnormalities and clinical symptoms associated with PTSD. Discussion of these models is beyond the scope of this article and the reader is referred to recent reviews for more details (Friedman, 1988; Kolb, 1987; van der Kolk, 1987; Kosten and Krystal, 1988; van der Kolk *et al.*, 1985). All of these models presuppose hyperarousal of the central noradrenergic system and focus especially on the locus ceruleus because it is instrumental in the neurobiology of arousal and panic.

Kolb (1987) has postulated that the excessive and prolonged high intensity stimulation from traumatic exposure produces cortical neuronal and synaptic changes in patients with chronic PTSD. Therefore, he hypothesizes that the conditioned fear response of PTSD is associated with alteration in brain functions that control aggressive expression and the sleep-dream cycle. This model accounts for the dramatic psychophysiological response in PTSD patients following exposure to traumagenic stimuli.

van der Kolk and associates (1985) have proposed that the animal model of learned helplessness to inescapable shock may be directly applicable to PTSD. They hypothesize that long-term potentiation of locus ceruleus pathways to the hippocampus and amygdala may produce the hyperarousal, traumatic nightmares, and flashbacks that characterize PTSD. Such a theory also suggests that fluctuations in endogenous opioid levels will affect the response to traumagenic stimuli since the locus ceruleus is inhibited by opioids. The inescapable shock theory offers a neurobiological rationale for stress induced analgesia and for the "action junkie" behavior that is sometimes considered secondary to PTSD. It also has implications for opiate addiction that will be discussed later.

van der Kolk (1987) and Friedman (1988) have independently suggested that kindling is a neurobiological model that may be as applicable to PTSD as it is to a cocaine model of psychosis (Post and Kopanda, 1976). Kindling is a process by which neuroanatomic structures, especially those in the limbic system, become increasingly sensitized following repeated exposure to electrical stimulation or cocaine-like drugs. Kindling can lead progressively to profound neurophysiological abnormalities such as grand mal seizures or to the progressive development of aberrant behavior. According to this model, chronic central sympathetic arousal in PTSD, mediated by the locus ceruleus, kindles limbic nuclei thereby producing a stable neurobiological abnormality. Kindling would explain to the stability of PTSD—if untreated it can persist for decades (Archibald and Tuddenham, 1965). This model also suggests that an anti-kindling drug such as carbamazepine might be pharmacologically efficacious in PTSD.

BIOLOGICAL APPROACHES TO DIAGNOSIS

Among biological diagnostic techniques that have been tested are psychophysiological assessment, the dexamethasone suppression test (DST), the sleep EEG, sodium lactate infusion and the sodium amytal interview. In this section I will review the applicability of these diagnostic techniques to PTSD and evaluate their potential for distinguishing PTSD from major depressive disorder (MDD) and panic disorder (PD) (Table II).

Psychophysiological Assessment

Currently the best and most specific biological diagnostic test for PTSD is psychophysiological assessment. This diagnostic technique is based on the fact that traumagenic stimuli elicit sympathetic hyperarousal as discussed under

section Sympathetic Nervous System (Blanchard *et al.*, 1982; Malloy *et al.*, 1983; Kolb, 1987; Pitman *et al.*, 1987). This technique is both sensitive and powerful when one uses a general stimulus such as an audiotape of combat sounds or a visual excerpt from a movie such as *Platoon.* It is even more discriminatory when the provocative stimulus is an individualized autobiographical traumatic anecdote (Pitman *et al.*, 1987).

Exposure to traumagenic stimuli may also have practical applicability as a clinical paradigm for testing biological markers other than sympathetic arousal such as HPA axis function or stress induced analgesia. In the development of standard diagnostic approaches, however, biological markers in PTSD patients should be assessed both at baseline and immediately after provocation by traumagenic stimuli.

Dexamethasone Suppression Test

The dexamethasone suppression test (DST—Carroll *et al.*, 1981) has enjoyed wide use in diagnosing major depressive disorder (MDD). It is based on the fact that MDD is a disorder that is associated with hyperfunctioning of the HPA system. For this reason, dexamethasone, which normally suppresses HPA activity, cannot do so in patients with MDD. Depressed patients, therefore, are often "nonsuppressors" when challenged by the DST. In an earlier article (Friedman, 1988), I suggested that DST might be useful for distinguishing PTSD from MDD. After all, PTSD appears to be associated with hypofunctioning of the HPA system whereas MDD seems to be just the opposite. Therefore, I predicted that PTSD patients would have a normal DST; they would be suppressors, while patients with MDD would be nonsuppressors. The work of Kudler *et al.* (1987) was consistent with this prediction; patients with PTSD alone were suppressors while those with *both* PTSD and MDD were nonsuppressors following a dexamethasone challenge. Subsequently, Halbreich and associates (1988) confused the issue when they compared DST responses of patients with MDD alone with a second group that had *both* MDD and PTSD. This time the MDD+PTSD patients were suppressors in contrast to MDD alone patients who were nonsuppressors. These results indicate that when PTSD and MDD coexist in the same patients, PTSD induced HPA hypofunction may neutralize MDD induced HPA hyperfunction. From the practical standpoint of clinical diagnosis, Halbreich *et al.'s* results have two implications. First of all, they suggest that the DST may have limited value in distinguishing PTSD from MDD. Second, and more importantly, these results suggest that when both PTSD and MDD occur simultaneously, each may alter the biological expression of the other.

Table II. Biological Diagnostic Tests for PTSD[a]

		PTSD	MDD	PD
I.	Psychophysiological Responses to Traumagenic Stimuli			
	Sympathetic arousal	+	–	–
	Stress induced analgesia	+	–	–
II.	HPA Axis Abnormalities			
	DST	–	+	–
	Urinary cortisol	↓	↑	?
III.	Sleep EEG Abnormalities			
	Initiating and maintaining sleep	↓	↓	↓
	Movements during sleep	↑	0	↑
	Stage 1 and stage 2	↑	0	0
	Delta	↓	↓	0
	REM	↑/↓	↑/0	0
	REM latency	↑/↓	↓	0
IV.	Sodium Lactate Infusion			
	Panic attacks	?	–	+
	Flashbacks	?	–	–
V.	Sodium amytal interview	+	–	–

[a] + = proven diagnostic value, – = no apparent diagnostic value, ? = unknown diagnostic value, ↓ = reduced, 0 = no change, ↑ = increased.

Sleep EEG

Investigations on the sleep EEG of depressed patients have shown that MDD is reliably associated with alterations in sleep architecture. Specifically, depressed patients exhibit reduced REM latency, reduced Delta sleep, and the duration of the first REM period is prolonged in MDD (Akiskal, 1983; Dube *et al.*, 1986; Kupfer and Thase, 1983; Ross *et al.*, 1988). As discussed under Sleep and Dreaming earlier and shown in Table II, it would appear that there might be enough differences between MDD and PTSD to predict that the sleep EEG will play an important role in the differential diagnosis of MDD vs PTSD. There is a problem with such a prediction. First of all, if (as suggested above, under Dexamethasone Suppression Test with regard to the DST) the simultaneous occurrence of MDD and PTSD alters the unique biological expression of each disorder, then the sleep EEG may also lose its specificity in patients who have both depression and PTSD. Indeed, such a possibility may explain some controversies in the literature and especially why some investigations have observed sleep EEG findings in PTSD patients that look more like expected results in depression (Greenberg *et al.*, 1972; Kauffman *et al.*, 1987, Van Kammen *et al.*, 1987).

To summarize, the potential usefulness of the sleep EEG in distinguishing MDD from PTSD has not been adequately tested. Perhaps it will be more useful

for future studies to focus primarily on the length of the first REM period rather than the total nocturnal percentage of REM sleep (Ross *et al.*, 1988). Undoubtedly, future studies will have to state quite explicitly whether their clinical populations meet diagnostic criteria for MDD, PTSD, or both.

On the other hand, the sleep EEG should easily distinguish PTSD from PD. There is apparently no disturbance of the sleep architecture in PD although panic patients do exhibit difficulty initiating and maintaining sleep and, like PTSD patients, show increased body movements while asleep (Dube *et al.*, 1986; Hauri *et al.* 1989).

Sodium Lactate Infusion

One of the most definitive diagnostic tests for PD is the sodium lactate infusion. Pitts and McClure's (1967) original observation that intravenous administration of sodium lactate can precipitate panic attacks in patients with PD has been replicated by many investigators. PD and PTSD share many characteristics in common. Both disorders may be associated with locus ceruleus dysregulation since both exhibit sympathetic hyperarousal and sudden surges of anxiety. In addition, PTSD flashbacks may meet DSM-III-R diagnostic criteria for panic attacks (Mellman and Davis, 1985). For these reasons, it would be very interesting to learn whether sodium lactate can induce PTSD symptoms as it can panic attacks. To date, the only report on this subject is quite confusing (Rainey *et al.*, 1987). Although the authors report that lactate infusion precipitated flashbacks in all seven subjects, only one such "flashback" was a reexperiencing of combat trauma. All other "flashbacks" occurred in a hospital setting more comparable to the laboratory experimental situation than to the combat trauma responsible for the later development of PTSD. Furthermore, since all patients met DSM-III-R criteria for PD as well as PTSD, their susceptibility to sodium lactate may differ considerably from the responsivity of PTSD patients who do not simultaneously meet DAM-III-R criteria for PD. In my opinion, it is still unclear whether PTSD patients will respond to a lactate infusion. It is an important question that needs to be investigated systematically. Furthermore, other established provocative tests for PD such as carbon dioxide inhalation (Fryer *et al.*, 1987) and yohimbine challenge (Charney *et al.*, 1987) also need to be explored with PTSD patients.

Sodium Amytal Interview

PTSD has revived interest in narcosynthetic exploration of repressed traumatic experiences or dissociative episodes triggered by traumagenic stimuli (Kolb, 1985). After decades of neglect, the sodium amytal interview is proving

Table III. Response to Medicatioon: PTSD, MDD, and PD[a]

	PTSD	MDD	PD
Tricyclic Antidepressants	+	+	+
MAO Inhibitors	+	+	+
Carbamazepine	(+)	?	0
Lithium	(+)	+	0
Benzodiazepines	(+)	–	+
Alprazolom	(+)	+	+
Propranolol	(+)	–	+
Clonidine	(+)	–	(+)
Neuroleptics	±	±	0

[a] + = proven therapeutic efficacy, (+) = promising uncontrolled trials, 0 = ineffective, – = worsens condition.

to be a useful clinical tool for identifying catastrophic stressors that are too terrifying for discussion in the normal state of consciousness. Clearly, this diagnostic technique has a unique applicability to PTSD in contrast to MDD or PD.

As defined by Kolb (1985), narcosynthesis is drug-induced recall of repressed material through an abreactive experience. Through this procedure, repressed material becomes consciously available for later integration and synthesis by the personality. The amytal interview is not an end in itself but rather a technique for exposing material through narcosynthetic abreaction that must be worked through in subsequent psychotherapy. Candidates for this approach are individuals who have complete or partial amnesia for recurrent episodes of abnormal behavior in which they may become aggressively threatening or violent. Such dissociative episodes are often precipitated by traumagenic stimuli and seem more likely to occur if the patient has been drinking beforehand.

The key to the narcosynthetic approach is videotaping the entire session. After full recovery of consciousness, the patient reviews the entire tape with his or her therapist so that recently repressed information can now be incorporated into ongoing psychotherapy. The reader is referred to Kolb (1985) for further details on indications, contraindications, and the specific technique for the amytal interview.

Differential Diagnosis: PTSD, MDD, and PD

Since PTSD shares many symptoms in common with MDD and PD, it is useful to review current knowledge on biological diagnostic tests to clarify their distinguishing features as well as their similarities.

PTSD and MDD are both associated with symptoms such as dysphoria, guilt, grief, anhedonia, irritability, social withdrawal, and insomnia. In addition, both disorders respond to some of the same medications (shown in Table III and discussed below). Likewise PTSD and PD are anxiety disorders marked by sympathetic hyperarousal, an association with depressive symptoms, panic attacks, responsivity to similar medications (see Table III), and a hypothesized locus ceruleus dysregulation.

In my opinion, the observations tabulated in Table II are consistent with the hypothesis that each of these three disorders has a unique biological profile that can be detected by appropriate diagnostic techniques. It is necessary to sound two cautionary notes about the data summarized in Table II. First of all, it is premature to be dogmatic about any of these findings on PTSD, given the general paucity of studies. Second, since DST results (Halbreich *et al.*, 1988) suggest that when PTSD and MDD occur simultaneously, each may alter the biological expression of the other, further research is needed in which PTSD, MDD, and PD are compared systematically in the same experimental protocol.

To summarize, as shown in Table II, the psychophysiological response to traumagenic stimuli is the hallmark of PTSD with regard to hyperarousal of the sympathetic nervous system and as manifested by the endogenous opioid mobilization associated with stress-induced analgesia. Although PD is also marked by hyperarousal of the adrenergic system, panic attacks are spontaneous events (rather than a response to emotionally charged stimuli) and are essentially a physiological event devoid of the psychological meaning associated with PTSD episodes. The distinctive HPA hyperactivity of MDD contrasts with HPA hypoactivity in PTSD. For practical purposes, since the DST is normal in PTSD and urinary cortisol levels are not routinely obtained, testing the HPA axis may have limited value in the clinical diagnosis of PTSD. All three disorders show sleep EEG abnormalities and all three exhibit difficulties initiating and maintaining sleep. Only PTSD and MDD appear to exhibit alterations in the sleep architecture as discussed previously. The sodium lactate infusion has not been adequately tested in PTSD as noted above. Finally, the sodium amytal interview is uniquely applicable to PTSD.

CLINICAL PSYCHOPHARMACOLOGY

From our current understanding it appears that any drug that can reduce excessive noradrenergic activity will be beneficial in PTSD. This might be accomplished by direct antagonism of sympathetic nervous system arousal (propranolol and other beta-adrenergic blocking agents), or by reduction of brain locus ceruleus activity via inhibiting alpha 2 adrenergic receptors (clonidine, tricyclic antidepressants). If PTSD results form limbic kindling (Friedman,

1988; van der Kolk, 1987) an anti-kindling agent such as carbamazepine might also be effective.

Most of the information on pharmacotherapy comes from open trials and case reports. A number of double-blind investigations are currently in process and a few preliminary reports have been presented. Given the current paucity of data from controlled clinical trials, it should come as no surprise that prescribing practices may differ widely from one place to another. For example, at one VA hospital 59% of all PTSD patients received tricyclic antidepressants either exclusively (38%) or in combination with other psychotropic agents (Embry and Callahan, 1988). At another VA hospital, 71% of PTSD patients received benzodiazepines either exclusively (36%) or in combination with other drugs (Ciccone *et al.*, 1990).

Tricyclic Antidepressants

Several clinical reports indicate that tricyclic antidepressants (TCAs) may be effective drugs for PTSD. Published observations suggest that TCAs reduce specific PTSD symptoms such as hyperarousal, intrusive recollections, flashbacks, and traumatic nightmares. Although the antidepressant action of TCAs is often useful against depressive symptoms that may be associated with PTSD, the primary therapeutic target symptoms under discussion here are PTSD and not MDD symptoms. Anecdotal reports and open trials using rating scales have generally reported that TCAs reduce DSM-III-R intrusive recollection and hyperarousal symptoms but have little effect on avoidant symptomatology (Blake, 1986; Bohnlein *et al.*, 1985; Burstein, 1982; Embry and Callahan, 1988; Falcon *et al.*, 1985; Friedman, 1981, 1988; Marshall, 1975; van der Kolk, 1987). Similar results have been obtained with different traumatized cohorts such as accident victims, burn patients, combat veterans, and Cambodian concentration camp survivors. Recently Davidson *et al.* (1988) and Frank *et al.* (1988) presented preliminary reports on TCA double-blind comparisons. Davidson *et al.* conducted an 8-week double-blind randomized trial of amitriptyline vs placebo. They found that amitriptyline was most effective in patients who had depressive symptoms and that this drug did not appear to have specific effects on either intrusive or avoidant PTSD symptoms. In contrast, Frank *et al.* (1988), conducting a randomized double-blind trial of imipramine, phenelzine (an MAO inhibitor), and placebo observed moderate reduction in both intrusive and avoidant PTSD symptoms with greater effects on intrusive symptoms. Their observation that improvement in PTSD symptoms was independent of the antidepressant response to imipramine conflicts directly with Davidson *et al.'s* conclusions. Clearly there is need for additional research since these results cannot be reconciled.

MAO Inhibitors

MAO inhibitors (MAOIs) have received attention since Hogben and Cornfield (1981) reported that they reduced panic, anxiety, insomnia, and intrusive symptoms in five combat veterans with PTSD. MAOIs are attractive agents to consider because of their proven efficacy against the sympathetic dysregulation of panic disorder, their antidepressant activity and their inhibition of REM sleep. Phenelzine is the only MAOI that has been studied and most reports describe open trial case reports on very few patients (Shen and Park, 1983; Milanes *et al.*, 1984). In two larger studies, Davidson *et al.* (1987) and Lerer *et al.* (1987) conducted open trials on 11 and 22 combat veterans, respectively. Both groups observed that phenelzine's primary PTSD effect was on intrusive rather than avoidant symptoms although reduction in general anxiety and depressive symptoms were also prominent. The only randomized double-blind trial has been Frank *et al.'s* comparison of imipramine, phenelzine, and placebo discussed above. These investigators reported that phenelzine was even more effective than imipramine against intrusive symptoms. It produced little improvement in avoidant symptoms. The therapeutic efficacy of MAOIs (like imipramine) in this study was completely independent of its antidepressant effect.

The decision to prescribe phenelzine will have to take into consideration a realistic expectation of patient compliance with regard to dietary restrictions and abstention from alcohol, opiates, and other drugs. Therefore, high rates of alcoholism and chemical abuse/dependency in combat veterans with PTSD (Branchy *et al.*, 1984; Keane *et al.*, 1988) may preclude extensive use of phenelzine, efficacy notwithstanding.

Carbamazepine

Carbamazepine is an anticonvulsant that was first introduced into psychiatry by Post and Kopanda (1976), who suggested that it be prescribed in lithium-refractory bipolar affective disorder. They based this suggestion on a kindling model of endogenous psychosis.

As noted above, kindling is a neurobiological model that may also be applicable to PTSD (Friedman, 1988; van der Kolk, 1987). For this reason, two investigations have monitored the efficacy of carbamazepine in ten PTSD patients. Seven patients showed marked reductions in intensity and frequency of the intrusive or "reexperiencing" symptoms of PTSD such as recurrent nightmares, flashbacks, and intrusive recollections (Lipper *et al.*, 1986). A second open-trial study by Wolf *et al.* (1988) showed alleviation of impulsivity, violent behavior, and angry outbursts in 10 Vietnam combat veterans with PTSD. Since there has been speculation that complex partial seizures may cause a syndrome

similar to PTSD (Greenstein *et al.*, 1986; Stewart and Bartucci, 1986), Wolf *et al's.*, results are especially notable since all of their carbamazepine patients had normal EEGs and had no symptoms of temporal lobe epilepsy.

Finally, it should be noted that despite the many similarities between PTSD and PD with respect to sympathetic hyperarousal, kindling may not be an appropriate model for PD. Uhde *et al.* (1988) recently reported on a 3-week double-blind trial of carbamazepine vs placebo in 14 patients with PD. In contrast to its therapeutic value in PTSD, carbamazepine was not effective in PD.

Propranolol

Propranolol is an adrenergic beta-blocker that has documented efficacy in anxiety (Suzman, 1971; Tanna *et al.*, 1977; Tyrer and Lader, 1974) and in panic disorder (Ravaris *et al.*, 1986). As noted above, it is an attractive drug to consider because it would be expected to antagonize the peripheral and (probably the) central sympathetic hyperarousal associated with PTSD. Another advantage of propranolol is that it is a non-benzodiazepine anxiolytic that can be prescribed without fear of fostering addiction or chemical abuse/dependence in susceptible PTSD patients. In an open trial of propranolol in 14 Vietnam veterans who received 120-160 mg daily for 6 months, most patients reported improvement with specific reductions in nightmares, intrusive recollections, hypervigilence, insomnia, startle responses, and angry outbursts (Kolb *et al.*, 1984). A controlled trial of up to 2.5 mg/kg/day propranolol in 11 sexually or physically abused children with acute PTSD (Famularo *et al.*, 1988) demonstrated significant reduction of intrusive and arousal symptoms. When placebo was substituted for propranolol, the children's symptoms returned to predrug intensity.

Clonidine

Clonidine is an alpha 2 adrenergic agonist currently used in hypertension and opiate withdrawal. It reduces central adrenergic activity by reducing locus ceruleus activity. For that reason it holds out promise as an effective antidote to the adrenergic hyperactivity associated with anxiety disorders. The only information on clonidine in PTSD comes from an open trial in nine Vietnam veterans who received a daily dose of 0.2-0.4 mg (Kolb *et al.*, 1984). Eight patients had a favorable response marked by lessened explosiveness, reduced nightmares, improved sleep, lessened startle, intrusive thinking, and hyperalertness. As with propranolol, the authors were careful not to overstate their findings and urged others to conduct systematic controlled trials of both propranolol and clonidine to establish their usefulness in PTSD.

Benzodiazepines

Benzodiazepines are potent anxiolytics that have been prescribed widely for PTSD, despite the lack of proven efficacy in controlled trials. Use of benzodiazepines in PTSD, of course, carries with it the risk of addiction and chemical abuse/dependency in susceptible patients (Friedman, 1981, 1988; van der Kolk, 1987). Practical clinical concerns about addiction notwithstanding, the kindling model of PTSD indicates that there may be a neurobiological rationale for prescribing these drugs. Several studies have shown that benzodiazepine receptor binding is increased significantly during the development of limbic kindling (McNamara *et al.*, 1985; Morita *et al.*, 1985; Tietz *et al.*, 1985). This suggests that benzodiazepines and other GABA agonists or synergists might be particularly efficacious in PTSD.

Alprazolam

Alprazolam is a triazolo-benzodiazepine that apparently differs from other benzodiazepines because of its demonstrated antipanic and antidepressant properties (Feighner *et al.*, 1983; Sheehan, 1982). It is currently used widely in PTSD although there presently are no double-blind studies demonstrating its efficacy. In addition to concerns about addiction and dependence mentioned previously with regard to all benzodiazepines, alprazolam's pharmacokinetic properties have raised additional concerns. Specifically, its short half-life makes the risk of rebound anxiety and serious withdrawal symptoms greater for alprazolam than for other benzodiazepines that are eliminated more slowly (Higgitt *et al.*, 1985; Noyes *et al.*, 1985).

Lithium

Lithium has been suggested as an effective treatment for PTSD, even in patients with no personal or family history of bipolar or cyclothymic illness (Kitchner and Greenstein, 1985; van der Kolk, 1983). van der Kolk (1987) reported that 14 out of 22 PTSD patients tried on lithium reported markedly diminished autonomic hyperarousal, a decreased tendency to react to stress as if it were a recurrence of their original trauma, and a marked decrease in alcohol intake. van der Kolk stated that the therapeutic response to lithium in his patients was "clinically indistinguishable" from the aforementioned results with carbamazepine reported by Lipper *et al.* (1986). As with most other drugs reviewed in this section, there are no systematic double-blind trials of lithium in PTSD.

Neuroleptics

The last drugs to consider are the neuroleptics or antipsychotic agents. When disturbed Vietnam combat veterans first appeared in VA hospitals in the late 1960s and in the 1970s, many of them were prescribed neuroleptics. Psychiatrists impressed by the agitation, bizarre and explosive behavior, rage, anti-authoritarian beliefs merging into paranoia, and brief psychotic episodes that we now call flashbacks often chose a neuroleptic as the drug of first choice. Since that time, we have learned that adrenergic hyperarousal rather than psychotic thinking is the primary target in pharmacotherapy of PTSD. Reduction of DSM-III-R intrusive recollections and arousal symptoms by TCAs, MAOIs, or other drugs is often sufficient to reduce or eliminate psychotic appearing manifestations of PTSD in most patients. Having learned after almost two decades of misuse and overuse of antipsychotic agents, it can now be stated that neuroleptics have no place in the *routine* treatment of PTSD.

I am not saying that neuroleptics have no value in pharmacotherapy for this disorder, but that they should be used judiciously as a second or third choice following clinical trials of TCAs or other potential first-line drugs. Indications for neuroleptics include aggressive psychotic symptoms (frequently paranoid), overwhelming anger, fragmented ego boundaries, self-destructive behavior, and frequent flashback episodes characterized by visual and auditory hallucinations of traumatic events (Atri and Gilliam, 1988; Friedman, 1981, 1988; Walker, 1982). Mueser and Butler's (1987) report on five Vietnam veterans with combat-related PTSD who had auditory hallucinations suggests that there may be a subgroup among PTSD patients for whom neuroleptics are specifically indicated.

Comparative Pharmacotherapy: PTSD, MDD, and PD

Although numerous psychotropic agents have been used for PTSD, there is only one double-blind investigation suggesting that both imipramine and phenelzine have specific efficacy against both intrusive and avoidant symptoms (Frank *et al.*, 1988). A second double-blind amitriptyline vs placebo trial must be considered equivocal since amitriptyline was most effective in depressed PTSD patients and showed little therapeutic specificity against the symptoms of PTSD (Davidson, *et al.*, 1988). With the exception of one study with propranolol in traumatized children, promising claims for the effectiveness of other drugs have not been validated in double-blind clinical trials.

Table III shows similarities and differences in the psychopharmacologic spectrum of action for PTSD, MDD and PD. All three disorders appear to respond to TCAs, MAOIs and probably to alprazolam. Carbamazepine and lith-

ium which may be effective in PTSD and MDD are without potency in PD. Although both drugs are efficacious in bipolar affective disorder, only lithium has proven therapeutic value in MDD. Benzodiazepines and anti-adrenergic agents such as propranolol and clonidine, which may be useful in PTSD and PD, can worsen the symptoms of MDD. Finally neuroleptics which may be useful in a carefully selected minority of PTSD cases have limited usefulness in psychotic MDD and are of no value in PD. To summarize, it can be seen from Tables II and III that despite considerable overlap in diagnostic abnormalities and responsivity to pharmacologic agents, PTSD, MDD, and PD appear each to have unique biological characteristics.

PTSD AND CHEMICAL ABUSE/DEPENDENCY

Most clinicians who treat combat-related PTSD readily acknowledge that therapy is often complicated by coexisting symptoms of alcohol or other chemical abuse/dependency. This clinical impression is confirmed by published reports indicating that 60-80% of patients seeking treatment for PTSD have concurrent diagnoses of substance abuse or dependence (Branchy *et al.*, 1984; Keane *et al.*, 1988). Some have argued that such high rates of substance abuse are due to the fact that alcohol and other drugs were extremely available to military personnel stationed in Vietnam during the war (Sapol and Roffman, 1969; Wedding, 1987). This cannot explain, however, why veterans with higher levels of combat exposure are more likely to abuse alcohol than those who saw considerably less combat (Keane *et al.*, 1988). Indeed, the latter finding suggests that neurobiological alterations associated with PTSD make affected individuals more susceptible to alcohol and illicit drug use.

Among the biological abnormalities occurring in PTSD, sympathetic nervous system hyperarousal and chronic lowering of endogenous opioid levels are most likely to generate susceptibility to chemical abuse/dependency. Any drug that can suppress central adrenergic activity such as alcohol, central depressants, marijuana, or opiates will produce temporary relief in the person suffering from PTSD. Furthermore, the possibility of a chronic opioid deficiency (indicated by lowered pain thresholds) suggests that PTSD patients might successfully ameliorate intolerable symptoms with heroin, methadone, and other opiates. Kosten and Krystal (1988) have elegantly reviewed the biological basis for PTSD symptoms and substance abuse. Arguing theoretically from van der Kolk's inescapable shock model of PTSD, they speculate that "use of ethanol or other drugs such as heroin in acute stress settings of war is an active adaptive style" and that "individuals with a history of recreational substance abuse may be more prone to 'self-medicate'" (Kosten and Krystal, 1988, p. 60). They also point out that during the vicious addiction-withdrawal cycle, the adrenergic

arousal associated either with alcohol or opiate withdrawal will trigger a conditioned emotional response associated with PTSD symptoms. In other words, the normal difficulties of treating chemical dependency are multiplied by the complex risk of exacerbating PTSD symptoms. This may be an even greater problem in cases of opiate dependence since heroin not only dampens adrenergic hyperarousal but may also serve to replenish an endogenous opioid system that has been depleted because of the pathophysiology of PTSD.

Although it is possible that central stimulants effectively relieve the dysphoria of PTSD, especially when depression is also present, one might predict on neurobiological grounds that the incidence of cocaine and amphetamine abuse among PTSD patients will be lower than expected. This is because central stimulants will facilitate sympathetic hyperarousal thereby exacerbating PTSD symptoms. To my knowledge this has not been studied systematically. In my own clinical experience, however, PTSD patients do not like the heightened emotional state produced by cocaine, amphetamines, and other stimulants. They generally prefer alcohol, marijuana, central depressants, or opiates. Furthermore, cocaine and stimulant users with PTSD are usually also dependent on alcohol, marijuana, and opiates, etc.

When PTSD and chemical abuse/dependency occur simultaneously, they must be treated simultaneously. Rigid adherence to the generic treatment formuli found in many alcohol and drug rehabilitation programs is a prescription for failure. This is because the complex interrelationships between intrapsychic, behavioral and biological aspects of PTSD and concurrent chemical abuse/dependency demand a comprehensive approach. A detailed description of treatment strategies for patients who carry the dual diagnosis of PTSD and chemical abuse/dependency is beyond the scope of this article. Psychopharmacological strategies to be integrated in such an approach may include disulfram (Antabuse) for alcohol dependence and the opiate antagonist naltrexone. Kosten and Krystal (1988) have suggested that the mixed opiate agonist-antagonist buprenorphine may be uniquely suited to "suppress conditioned noradrenergic activation and maintain antagonist self-administration" (p. 62) in PTSD patients undergoing opiate withdrawal. The bottom line, as noted by Stone (1988) is for a therapeutic approach that respects both the psychological and neurobiological implications of autopharmacotherapy in patients who suffer from PTSD and chemical abuse/dependency.

CONCLUSION

1. The unique pattern of biological abnormalities associated with PTSD appear to differentiate this disorder from MDD and PD.

2. Provocative laboratory tests that probe PTSD-induced alterations in noradrenergic activity, the HPA axis, the endogenous opioid system, and the sleep cycle should enable us to achieve greater precision in diagnosing PTSD.

3. Almost every conceivable psychotropic agent has been reported to have efficacy in PTSD. Almost all of these claims are based on clinical anecdotes or open drug trials except for two double-blind investigations on imipramine, phenelzine, and amitriptyline, and one controlled study with propranolol.

4. Neurobiological alterations associated with PTSD may make affected individuals more susceptible to alcohol, opiate, and other illicit drug use. The complex interrelationships between intrapsychic, behavioral, and biological aspects of PTSD and concurrent chemical abuse/dependency demand a comprehensive approach to both problems simultaneously.

5. Successful pharmacotherapy for PTSD has generally provided alleviation of DSM-III-R intrusive recollections and arousal symptoms. Avoidant symptoms, impacted grief, guilt, rage, problems with intimacy, and moral pain do not appear to respond to medication. Therefore, it should be understood that drug treatment alone can never alleviate the suffering in PTSD. Pharmacotherapy is primarily useful as an adjunct to psychological (intrapsychic and/or behavioral) treatment of PTSD.

REFERENCES

Akiskal, H. S. (1983). Diagnosis and classification of affective disorders: New insights from clinical and laboratory approaches. *Psychiatr. Dev.* 2: 123-160.

Archibald, H. C., and Tuddenham, R. D. (1965). Persistent stress reaction after combat: A 20 year follow-up. *Arch. Gen. Psychiat.*, 12: 475-481.

Atri, P. B., Gilliam, J. H. (1990). Letter, *Am. J. Psychiat.* 146: 128.

Beard, G. M. (1869). Neurasthenia or nervous exhaustion. *Bost. Med. Surg. J.* 3: 217.

Blake, D. J. (1986). Treatment of acute posttraumatic stress disorder with tricyclic antidepressants. *South. Med. J.*, 79: 201-204.

Benedikt, R. A. and Kolb, L. C. (1986). Preliminary findings on chronic pain and posttraumatic stress disorder. *Am. J. Psychiat.* 143: 908-910.

Blanchard, E. G. Kolb, L. C., Pallmeyer, B. A., and Gerardi, R. J. (1982). A psychophysiological study of post traumatic stress disorder in Vietnam veterans. *Psychiat. Quart.*, 54: 220-229.

Boehnlein, J. K., Kinzie, J. D., Ben, R., *et al.* (1985). One-year follow-up study of posttraumatic stress disorder among survivors of Cambodian concentration camps. *Am. J. Psychiat.*, 142: 956-959.

Branchey, L., Davis, W., and Lieber, C. S. (1984). Alcoholism in Vietnam and Korea veterans: A long term follow-up. Alcoholism: *Clin. Exp. Res.*, 8: 572-757.

Brende, J. O. (1982). Electrodermal responses in post-traumatic syndromes. *J. Nerv. Ment. Dis.*, 170: 352-361.

Burstein, A. (1982). Treatment of post-traumatic stress disorder with imipramine. *Psychosomatics*, 25: 681-687.

Carroll, B. J., Feinberg, M., Greden, J. F., *et al.* (1981). A specific laboratory test for the diagnosis of melancholia. *Arch. Gen. Psychiat.*, 38: 15-22.

Charney, D. S., Woods, S. W., Goodman, W. K., and Heninger, G. K. (1987). Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. *Am. J. Psychiat.*, 144: 1030-1036.
Ciccone, P. E., Mazarek, A., Weisbrot, M., *et al.* (1990). Letter, *Am. J. Psychiat.* 146: 812.
Cohen, M. E., White, P. D., and Johnson, R. E. (1948). Neurocirculatory asthenia, anxiety neurosis or the effort syndrome. *Arch. Int. Med.*, 81: 260-281.
Cohen, M. E. and White, P. D. (1950). Life situations, emotions and neurocirculatory asthenia (anxiety neurosis, neurasthenia, effort syndrome). *Res. Publ. Assoc. Res. Nerv. Ment. Dis.*, 29: 832-864.
DaCosta, J. M. (1871). On irritable heart: A clinical study of a form of functional cardiac disorder and its consequences, *Am. J. Med. Sci.*, 61: 17-52.
Davidson, J., Lipper, S., Kilts, C. D., *et al.* (1985). Platelet MAO activity in posttraumatic stress disorder. *Am. J. Psychiat.*, 142: 1341-1343.
Davidson, J., Walker, J. I., and Kilts, C. (1987). A pilot study of phenelzine in the treatment of post-traumatic stress disorder. *Brit. J. Psychiat.*, 150: 252-255.
Davidson, J., Kudler, H., Smith, R., *et al.* (1988). Amitriptyline treatment of PTSD. Presented at 141st Annual Meeting, *American Psychiatric Association*, Montreal, PQ, May 7-12.
Dobbs, D., and Wilson, W. P. (1961). Observations on persistence of war neurosis. *Dis. Nerv. Sys.*, 21: 40-46.
Dube, S., Jones, D. A., and Bell, J. (1986). Interface of panic and depression: Clinical and sleep EEG correlates. *Psychiat. Res.*, 119: 119-133.
Embry, C. K. and Callahan, B. (1988). Effective pharmacotherapy for post-traumatic stress disorder. *VA Pract.*, 5: 57-66.
Falcon, S., Ryan, C., Chamberlain, K., and Curtis, G. (1985). Tricyclics: Possible treatment for posttraumatic stress disorder. *J. Clin. Psychiat.*, 46: 385-389.
Famularo, R., Kinscherff, R. and Fenton, T. (1988). Propranolol treatment for childhood posttraumatic stress disorder, acute type: A pilot study. *Am. J. Dis. Child.* 142: 1244-1247.
Feighner, J. P., Aden, G. C., Fabre, L. F., Rickels, K., and Smith, W. T. (1983). Comparison of alprazolam, imipramine and placebo in the treatment of depression. *J. Am. Med. Assoc.*, 249: 3057-3064.
Frank, J. B., Kosten, T. R., Dan, E., *et al.* (1988). Imipramine and phenelzine treatment of PTSD. Presented at 141st Annual Meeting, *Am. Psychiat. Assoc.*, Montreal, PQ, May 7-12.
Friedman, M. J. (1981). Post-Vietnam syndrome: recognition and management. *Psychosomatics*, 22: 931-943.
Friedman, M. J. (1988). Towards rational pharmacotherapy for post-traumatic stress disorder. *Am. J. Psychiat.*, 145: 281-285.
Fryer, M. R., Uy, J., Martinez, J., *et al.* (1987). CO_2 challenge of patients with panic disorder. *Am. J. Psychiat.*, 144: 1080-1082.
Gillespie, R. D. (1942). *Psychological Effects of War on Citizen and Soldier*, Norton, New York.
Greenberg, R., Pearlman, C. A. and Gampel, D. (1972). War neuroses and the adaptive function of REM sleep. *Brit. J. Med. Psychol.*, 45: 27-33.
Greenstein, R. A., Kitchner, I., and Olsen, K. (1986). Posttraumatic stress disorder, partial complex seizures, and alcoholism. *Am. J. Psychiat.*, 142: 1203.
Halbreich, U., Olympia, J., Glogowski, J., *et al.* (1988). The importance of past psychological trauma and pathophysiologic process as determinants of current biologic abnormalities. *Arch. Gen. Psychiat.*, 45: 293-294.
Hartshorne, H. (1863). On heart disease in the army. *Am. J. Med. Sci.*, 47: 89-92.
Hauri, P. J., Friedman, M. J., and Ravaris, C. L. (1989). Sleep in patients with spontaneous panic attacks. *Sleep* 12: 323-337.
Higgitt, A. C., Lader, M. H., and Fonagy, P. (1985). Clinical management of benzodiazepine dependence. *Brit. Med. J.*, 291, 688-690.
Hogben, G. L., and Cornfield, R. B. (1981). Treatment of traumatic war neurosis with phenelzine. *Arch. Gen. Psychiat.*, 38: 440-445.
Kardiner, A. (1941). The Traumatic Neuroses of War. *Psychosom. Med. Monogr. II-III*, National Research Council, Washington, D.C.
Kardiner, A., and Speigel, H. (1947). *The Traumatic Neuroses of War*, Paul Hoeber, New York.

Kauffman, C. D., Reist, C., Djenderedjian, A., *et al.* (1987). Biological markers of affective disorders and posttraumatic stress disorder: A pilot study with desipramine. *J. Clin. Psychiat.*, 48: 366-367.

Keane, T. M., Zimering, and R. T., Caddell, J. M. (1985). A behavioral formulation of posttraumatic stress disorder in Vietnam veterans. *Behav. Ther.*, 8: 9-12.

Keane, T. M., Gerardi, R. J., Lyons, J. A., *et al.* (1988). The interrelationship of substance abuse and posttraumatic stress disorder: Epidemiological and clinical considerations. *Rec. Dev. Alcohol.*, 6: 27-48.

Kitchner, I., and Greenstein, R. (1985). Low dose lithium carbonate in the treatment of post traumatic stress disorder: Brief Communication. *Milit. Med.*, 150: 378-381.

Kolb, L. C. (1985). The place of narcosynthesis in the treatment of chronic and delayed stress reactions of war. In Sonnenberg, S. M., Blank, A. S., and Talbott, J. A. (eds.), *The Trauma of War Stress and Recovery in Vietnam Veterans*, American Psychiatric Press, Washington, D.C., pp. 211-226.

Kolb, L. C. (1987). A neuropsychological hypothesis explaining post-traumatic stress disorders. *Am. J. Psychiat.*, 144: 989-995.

Kolb, L. C., Burris, and B. C., Griffiths, S. (1984). Propranolol and clonidine in the treatment of the chronic post traumatic stress disorders of war. In van der Kolk, B.A. (ed.), *Post-Traumatic Stress Disorder: Psychological and Biological Sequelae*, American Psychiatric Press, Washington, D.C.

Kosten, T. R. and Krystal, J. (1988). Biological mechanisms in post-traumatic stress disorder: Relevance for substance abuse. *Rec. Dev. Alcohol.*, 6: 49-68.

Kosten, T. R., Mason, J. W., Giller, E. L., *et al.* (1987). Sustained urinary norepinephrine elevation in post-traumatic stress disorder. *Psychoneuroendocrinology*, 12: 13-30.

Kosten, T. R., Giller, E. L., and Mason, J. W. (1988). Psychoendocrine assessment of PTSD. Presented at 141st Annual Meeting, *American Psychiatric Association*, Montreal, PQ, May 7-12.

Kramer, M. (1979). Dream disturbance. *Psychiat. Ann.*, 9: 50-60.

Kramer, M., and Kinney, L. (1985). Is sleep a marker of vulnerability to delayed post traumatic stress disorder? *Sleep Res.*, 14: 181.

Kramer, M., and Kinney, L. (1988). Sleep patterns in trauma victims with disturbed dreaming. *Psychiat. J. Univ. Ottawa*, 13: 12-16.

Kramer, M., Kinney, L., and Scharf, M. (1982). Sleep in delayed stress victims. *Sleep Res.*, 11: 113.

Kudler, H., Davidson, J., and Meador, K. (1987). The DST and post-traumatic stress disorder. *Am. J. Psychiat.*, 144: 1068-1071.

Kupfer, D. J., and Thase, M. E. (1983). The use of the sleep laboratory in the diagnosis of affective disorders. *Psychiat. Clin. North Am.*, 6: 3-25.

Lavie, P., Hefez, A., Halperin, G., *et al.* (1979). Long-term effects of traumatic war-related events on sleep. *Am. J. Psychiat.*, 136: 175-178.

Lerer, B., Ebstein, R., Shestatsky, M., *et al.* (1987). Cyclic AMP signal transduction in post-traumatic stress disorder. *Am. J. Psychiat.*, 144: 1324-1327.

Lerer, B., Bleich, A., and Kotler, M. (1987). Post-traumatic stress disorder in Israeli combat veterans: Effect of phenelzine treatment. *Arch. Gen. Psychiat.*, 44: 976-981.

Lewis, T. (1917). Reports upon soldiers returned as cases of Disordered Action of the Heart (DAH) or Valvular Disease of the Heart (VDH). *Medical Research Committee (National Health Insurance)*, His Majesty's Stationary Office, London.

Lipper, S., Davidson, J. R. T., Grady, T. A., *et al.* (1986). Preliminary study of carbamazepine in post-traumatic stress disorder. *Psychosomatics*, 27: 849-854.

Malloy, P. F., Fairbank, J. A., and Keane, T. M. (1983). Validation of a multimethod assessment of posttraumatic stress disorders in Vietnam veterans. *J. Consult. Clin. Psychol.*, 51: 488-494.

Marshall, J. R. (1975). The treatment of night terrors associated with the post-traumatic syndrome. *Am. J. Psychiat.*, 132: 293-295.

Mason, J. W., Giller, E. L., Kosten, T. R., *et al.* (1985). Elevation of urinary norepinephrine/cortisol ratio in post-traumatic stress disorder. New Research Program and Abstracts, 138th Annual Meeting of the *American Psychiatric Association*, Washington, D. C.

Mason, J. W., Giller, E. L, Kosten, T. R., Ostroff, R., and Harkness, L. (1986). Urinary free-cortisol in post-traumatic stress disorder. *J. Nerv. Ment. Dis.*, 174: 145-149.

McNamara, J. O., Bonhaus, D. W., Shin, C., Crain, B. J., Gellman, R. L., and Giacchino, J. L. (1985). The kindling model of epilepsy: A critical review. *CRC Crit. Rev. Clin. Neurobiol.*, 1: 341-391.

Mellman, T. A., and Davis, G. C. (1985). Combat-related flashbacks in post-traumatic stress disorder: Phenomenology and similarity to panic attacks. *J. Clin. Psychiat.*, 46: 379-382.

Milanes, F. S., Mack, C. N., and Dennison, J. (1984). Phenelzine treatment of post-Vietnam stress syndrome. *VA Practit.*, 40-49.

Morita, K., Okamoto, M., Seki, K., and Wada, J. A. (1985). Suppression of amygdala-kindled seizures in cats by enhanced GABAergic transmission in the substantia innominata. *Exp. Neurol.*, 89: 225-236.

Mueser, K. T., and Butler, R. W. (1987). Auditory hallucinations in combat-related chronic post-traumatic stress disorder. *Am. J. Psychiat.*, 144: 299-302.

Noyes, R., Clancy, J., Coryell, W. H., Crowe, R. R., Chaudhry, D. R., and Domingo, D. V. (1985). A withdrawal syndrome after abrupt discontinuation of alprazolam. *Am. J. Psychiat.*, 142: 114-116.

Perry, B. D., Giller, E. L., and Southwick, S. M. (1987). Altered platelet alpha 2.adrenergic binding sites in post-traumatic stress disorder. *Am. J. Psychiat.* 144: 1511-1512.

Perry, B. D., Southwick, S. M., and Giller, E. L. (1988). Adrenergic receptor regulation in PTSD. Presented at 141st Annual Meeting, *American Psychiatric Association*, Montreal, PQ, May 7-12.

Perry, S. W., Cella, D. F., Falkenberg, J., *et al.* (1987). Pain perception in burn patients with stress disorders. *J. Pain Sympt. Manag.*, 2: 29-33.

Pitman, R. K., Orr, S. P., Forgue, D. F., *et al.* (1987). Psychophysiologic assessment of post-traumatic stress disorder imagery in Vietnam combat veterans. *Arch. Gen. Psychiat.* 44: 970-975.

Pitman, R. K., van der Kolk, B., Orr, S. P., *et al.* (1990). Naloxone-reversible analgesic response to combat-related stimuli in post-traumatic stress disorder. *Arch. Gen. Psychiat.* 47: 541-544.

Pitts, F. N., Jr., and McClure, J. N., Jr. (1967). Lactate metabolism in anxiety neurosis. *N. Eng. J. Med.*, 277: 1329-1336.

Post, R. M., and Kopanda, R. T. (1976). Cocaine, kindling and psychosis. *Am. J. Psychiat.*, 133: 627-634.

Price, L. H., Charney, I. D. S., Rubin, A. L., and Heninger, G. R. (1986). Alpha-2 adrenergic receptor function in depression: The cortisol response to yohimbine. *Arch. Gen. Psychiat.*, 43: 849-858.

Rainey, J. M., Aleem, A., Ortiz, A., *et al.* (1987). A laboratory procedure for the induction of flashbacks. *Am. J. Psychiat.*, 144: 1317-1319.

Rapaport, M. H. (1987). Chronic pain and post-traumatic stress disorder. *Am. J. Psychiat.*, 144: 120.

Ravaris, C. L., Friedman, M. J., and Hauri, P. (1986). A controlled study of alprazolam and propranolol in panic disorder and agoraphobic patients. Presented at 139th Annual Meeting, *American Psychiatric Association*, Washington, D.C., May 10-16.

Ross, R. J., Ball, W., and Morrison, A. (1990). Letter. *Am. J. Psychiat.* (in press).

Ross, R. J., Ball, W. A., Sullivan, K. A., and Caroff, S. N. (1989). Sleep disturbance as the hallmark of post-traumatic stress disorder. *Am. J. Psychiat.*, 146: 697-707.

Sapol, E., and Roffman, R. A. (1969). Marijuana in Vietnam. *Journal of the American Pharmaceutical Association*, NS9, 615-630.

Schlossberg, A., and Benjamin, M. (1978). Sleep patterns in three acute combat fatigue cases. *J. Clin. Psychiat.*, 39: 546-549.

Shalev, A. Y., Bleich, A., and Ursano, R. J. (1990). Posttraumatic stress disorder: somatic comorbidity and effort tolerance. *Psychosomatics*, 31: 197-203.

Sheehan, D. V. (1982). Current perspectives in the treatment of panic and phobic disorders. *Drug Ther.*, 7: 179-193.

Shen, W. W., and Park, S. (1983). The use of monoamine oxidase inhibitors in the treatment of traumatic war neurosis: Case report. *Milit. Med.*, 148: 430-431.

Solomon, Z., and Mikulincer, M. (1987). Combat stress reaction, post-traumatic stress disorder and somatic complaints among Israeli soldiers. *J. Psychosom. Res.*, 31: 131-137.
Stewart, J. R., and Bartucci, R. J. (1986). Post-traumatic stress disorder and partial complex seizures. *Am. J. Psychiat.*, 143: 113-114.
Stone, A. (1988). Letter. *Am. J. Psychiat.* 145: 1485.
Suzman, M. M. (1971). The use of beta-adrenergic blockade with propranolol in anxiety syndrome. *Postgrad. Med. J.*, 47: 104-108.
Tanna, V. T., Penningroth, R. P., and Woolson, R. F. (1977). Propranolol in the treatment of anxiety neurosis. *Comp. Psychiat.*, 18: 319-326.
Tietz, E. I., Gomaz, F., and Berman, R. F. (1985). Amygdala kindled seizure stage is related to altered benzodiazepine binding site density. *Life Sci.*, 36: 183-190.
Tyrer, P. J. and Lader, M. H. (1974). Response to propranolol and diazepam in somatic anxiety. *Brit. Med. J.*, 2: 14-16.
Uhde, T. W., Stein, M. B., and Post, R. M. (1988). Lack of efficacy of carbamazepine in the treatment of panic disorder. *Am. J. Psychiat.*, 145: 1104-1109.
van der Kolk, B. A. (1983). Psychopharmacological issues in post-traumatic stress disorder. *Hosp. Commun. Psychiat.*, 34: 683-691.
van der Kolk, B. A. (1987). The drug treatment of post-traumatic stress disorder. *J. Affect. Dis.*, 13: 203-213.
van der Kolk, B. A., Blitz, R., Burr, W., Sherry, S., and Hartmann, E. (1984). Nightmares and trauma: A comparison of nightmares after combat with lifelong nightmares in veterans. *Am. J. Psychiat.*, 141: 187-190.
van der Kolk, B. A., Greenberg, M., Boyd, H., and Krystal, J. (1985). Inescapable shock, neurotransmitters, and addiction to trauma: Toward a psychobiology of post-traumatic stress. *Biol. Psychiat.*, 20: 314-325.
Van Kammen, W., Christiansen, C., Van Kammen, D., *et al.* (1987). Sleep and the POW experience: 40 years later. *Sleep Res.*, 16: 291.
Walker, J. I. (1982). Chemotherapy of traumatic war stress. *Milit. Med.*, 147: 1029-1033.
Wedding, D. (1987). Substance abuse in the Vietnam veteran. *AAOHN J.*, 35: 74-76.
Wolf, M. E., Alavi, A., and Mosnaim, A. D. (1988). Post-traumatic stress disorder in Vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine. *Biol. Psychiat.*, 23: 642-644.
Wood, P. (1941). DaCosta's Syndrome or Effort Syndrome. *Brit. Med. J.*, 1: 767, 805, 845.